Equillium, Inc. — Form 8-K
Filed November 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Equillium (market cap ~$7.1M) closed a $20M second tranche of a previously announced private placement on October 26, 2026, triggered by first patient dosing in the Phase 1 clinical trial of EQ504, an aryl hydrocarbon receptor modulator. Cash position of $53.3M as of September 30, 2026, rises to ~$72M pro forma post-October funding, with runway into 2029. Proof-of-mechanism data expected Q2 2027; proof-of-concept ulcerative colitis study planned for H2 2027.
Why this rating
Financing of $20M represents 280% of company market cap—critical lifeline. Phase 1 initiation and extended runway to 2029 validates clinical strategy and reduce near-term dilution risk.
Tradability signal
NO TRADE
No trade: only ~$46k traded in the last 30 min — too illiquid to enter and exit. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $1.34 ▲ 1.52% | at our read · unknown $1.32 | +10 min · unknown $1.36 ▲ 3.03% | +30 min · unknown $1.31 ▼ 0.76% | +1 hr · unknown $1.29 ▼ 2.27% | +4 hrs · unknown $1.27 ▼ 3.79% |
The stock had already moved -1.49% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.